Kedrion-Kamada collaboration, first patient enrolled in the clinical trial
Yet another milestone in the global Kedrion-Kamada collaboration for the development, manufacturing and distribution of a plasma-derived immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19). On Aug. 10, 2020 Kamada Ltd. announced that the first patient has been recruited to the Phase 1/2 clinical trial of its anti-SARS-CoV-2 plasma-derived immunoglobulin (IgG) product
Kedrion’s Mother and Child Health campaign for Asia and MEA announced
Details were unveiled during our first televised Regional Distributor Meeting on July 14th-15th
COVID-19. Kedrion partners with Columbia University Irving MC
Kedrion and Columbia University release video statements
Kedrion-Kamada collaboration, first batch of Covid-19 IG released in Israel
The two companies are now working to expand the Clinical Development Program to the US
Covid-19: plasma and Hyperimmune Immunoglobulins, ongoing activities
Plasma in the fight against COVID-19 Alongside the Italian National Health Service and hospitals for plasma therapy Industrial viral inactivation as an additional option Hyperimmune Immunoglobulins Contract Manufacturing in Italy Plasma in the fight against COVID-19 To cope with the serious health emergency caused by the SARS-Cov-2 pandemic, companies that produce plasma derivatives worldwide are
Kedrion and Kamada announce collaboration for Anti Covid-19 IgG
Kamada is Responsible for Product Development, Manufacturing, Clinical Development, and Regulatory Submissions, as well as Distribution in Territories not under Kedrion’s Responsibility Kedrion is Responsible for the Collection and Supply of Plasma from Convalescent COVID-19 Patients, Support of Clinical Development and Distribution in the U.S., Europe, Australia, and S. Korea Rehovot, Israel and Castelvecchio
Coronavirus, from Plasma an anti Covid-19 treatment
Kedrion’s commitment to find a treatment from convalescent patient plasma
Kedrion Statement on the novel Coronavirus
In accordance with international, national and local authority guidelines, Kedrion has acted immediately in dealing with the epidemiological emergency linked to the spread of the novel Coronavirus, and has taken all necessary measures to safeguard the health and safety of its employees and guarantee continuation of business activities. Paolo Marcucci, Chairman & CEO has stated:
Letter to patient associations and scientific organizations
Communication from Paolo Marcucci, Chairman & CEO of Kedrion
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy